Vertex Expands Rare Disease Portfolio with Deal to Acquire Crinetics for $10 Billion

Rare Daily Staff

Vertex Pharmaceuticals said it will acquire Crinetics Pharmaceuticals in a deal valued at about $10 billion, aiming to strengthen its presence in rare endocrine diseases and add new growth drivers beyond its core business.

Under the agreement, Vertex will pay $85 per share in cash for Crinetics, with the transaction expected to close in the third quarter of 2026, pending regulatory and shareholder approvals.

For Vertex, the move represents another step in diversifying beyond its long-dominant cystic fibrosis franchise, as it builds a broader pipeline across rare diseases and specialty conditions. Vertex plans to finance the acquisition through a mix of cash and debt, including $4.5 billion in committed bridge financing from major banks.

The acquisition brings Vertex a newly launched drug for the rare hormonal disorder acromegaly, as well as a late-stage experimental treatment for a genetic adrenal condition, both of which analysts view as potential blockbuster therapies.

Crinetics’ lead commercial product, Palsonify, became the first once-daily oral treatment approved for adults with acromegaly in the United States in 2025. The disease, typically caused by a benign tumor in the pituitary gland, leads to excessive growth hormone levels and serious complications if untreated. Existing therapies often require regular injections, whereas Palsonify offers a pill-based alternative.

Vertex said the drug has shown strong early uptake since its launch, supported by growing physician adoption and insurance coverage. The company plans to use its global commercial infrastructure to expand access to the therapy.

The deal also gives Vertex control of atumelnant, an experimental oral drug currently in phase 3 trials for congenital adrenal hyperplasia (CAH), a rare genetic disorder affecting roughly 17,000 patients in the United States. CAH disrupts hormone production and often forces patients to balance disease control with the side effects of long-term steroid use.

In mid-stage studies, atumelnant reduced excess androgen levels while allowing patients to remain on more natural, lower doses of steroids—a combination that has been difficult to achieve with existing treatments. The drug is also being studied for Cushing’s syndrome, another endocrine disorder.

Vertex expects the two lead assets to generate more than $5 billion in combined annual revenue at their peak. The company said the acquisition will contribute immediately to revenue growth and is projected to boost profitability by 2029.

“This is a strong strategic fit,” said Vertex CEO Reshma Kewalramani in a statement, citing Crinetics’ focus on serious diseases with well-understood biology and high unmet need.